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Catalytically active sGC is an obligatory heterodimer composed of ␣ and ␤ subunits. Each subunit type is encoded by two independent genes: GUCY1a3 (␣1) and GUCY1a2 (␣2); GUCY1b3 (␤1) and GUCY1b2 (␤2). The ␣1/␤1 sGC is the most highly expressed heterodimer in vascular tissues (20) . Several molecular mechanisms were implicated in downregulation of sGC expression and activity in vascular disease, including inhibition of transcription (1, 33, 34, 39, 47) , destabilization of mRNA (22) , and protein degradation in increased oxidative environment (3, 9, 14) . Systematic analysis of the NCBI nucleotide database identifies seven alternatively spliced transcripts for GUCY1A3 gene of the ␣1 subunit (␣1-Tr1 to ␣1-Tr7) and six splice transcripts for the GUCY1B3 gene of the ␤1 subunit (␤1-Tr1 to ␤1-Tr6) (42) . In addition to canonical full-length ␣1 (isoform A) and ␤1 (isoform 2) subunits, three more ␣1 protein isoforms (isoforms B, C, D) and five more ␤1 isoforms (isoforms 1, 3, 4, 5, 6) are predicted to be encoded by these transcripts. Our and other laboratories identified and characterized several sGC splice forms and demonstrated that their expression can modulate sGC function and enzymatic properties in vitro (4, 5, 7, 8, 43) . These and other studies strongly suggested that alternative splicing of sGC transcripts may be important in regulation of sGC function in vivo. However, splicing regulation of sGC and its biological role in vascular tissue was never previously examined.
In this study, we investigated the alternative splicing of ␣1 and ␤1 sGC genes in healthy human aortas and aortas with aneurysm. Our results indicate that altered splicing contributes to sGC dysfunction in aortas and may be a factor in vascular dysfunctions. Examination of expression of individual transcripts may be a useful tool in predicting changes in sGC function and activity in vascular tissue and may serve as a potential diagnostic tool for optimizing personalized sGCtargeted treatments.
MATERIALS AND METHODS
Collection of human aortic tissue samples. De-identified patient tissue samples were collected at the Department of Clinical Cardiothoracic Surgery at Herman-Memorial Hospital according to the protocol HSC-MS-10-0267 approved by Institutional Review Board Committee for the Protection of Human Subjects and conforming to the principles outlined in the Declaration of Helsinki and with patients' informed consent. Aortic samples were submerged in prechilled DMEM media right after the tissue removal during surgical repair of aortic aneurysm and stored on ice (no longer than 4 h) before snap freezing in liquid nitrogen. According to supplier's (Capital Biosciences) protocol, the samples from donors that succumbed to causes unrelated to aortic aneurysm were harvested within 2 h of death and frozen in liquid nitrogen. All samples were shipped on dry ice. For processing, each sample was thawed on ice and dissected in cold media to remove adventitia. Pieces of whole thickness of aortic wall, containing both intima and media layers, were snap frozen in liquid nitrogen and pulverized by pestle in a prechilled mortar. Aortic tissue powder was split for protein lysate preparation and RNA purification. Total RNA was purified using RiboPure kit (Life Technologies) according to manufacturer's instruction. For preparation of protein lysates, tissue powder was resuspended in cold 50 mM TEA buffer (pH 7.4) containing protease inhibitor cocktail (Sigma-Aldrich) and homogenized by Polytrone. Debris was discarded by centrifugation, whereas supernatant was sonicated. Cleared supernatants prepared by 100,000-g centrifugation for 1 h at 4°C were used for Western blotting and immunoprecipitation.
Quantitative and semi-quantitative reverse transcriptase-polymerase chain reactions. cDNA for analysis was prepared using highcapacity cDNA kit (Applied Biosystems). The semi-quantitative reverse transcriptase (qRT)-PCR assay for detection of ␣1 and ␤1 splice variants was performed as described previously (10) . Primer sets used for reverse transcriptase (RT)-PCR detection of individual splice transcripts, and amplicon length are described in Table 1 . Amplified PCR products were separated on 3% agarose gel and visualized by ethidium bromide. Electrophoretograms were quantified by densitometry using QuantityOne software (Bio-Rad). Identity of PCR bands was confirmed by direct sequencing. GAPDH levels were used as internal controls for normalization in quantitation of RT-PCR results. The following primers were used for GAPDH amplification: forward: 5=agaaggctggggctcatttg-3=; reverse: 5=-gtgatggcatggactgtggt-3=. Titration with different cDNA amounts was performed to ensure that quantification was used in the linear range of amplification. For qPCR analysis of sGC transcripts, commercial Hs01015574_m1 and Hs00168336_m1 assays (Applied Biosystems) were used to quantify the total levels of ␣1 and ␤1 sGC transcripts, respectively. Ribosomal 18S RNA (4308329, Applied Biosystems) was used as an endogenous control for normalization of qPCR results and calculation of ⌬CT values (comparative Ct values, where Ct is the PCR cycle when detection threshold is achieved). TaqMan reactions (Applied Biosystems) were performed according to the manufacturer's protocol. To estimate the fold changes in the level of transcripts between two groups, the ⌬⌬CT value was calculated as ⌬CT1 Ϫ ⌬CT2. The fold difference in the expression was calculated as 2
⌬⌬CT
. Western blot analysis and immunoprecipitation. Western blot analysis was performed as described previously (20) . Cleared supernatant fractions of protein lysates were separated by SDS-PAGE and transferred on PVDF membranes. For ␣1 sGC detection, primary monoclonal anti-␣1 antibodies (30) that recognize an epitope in the middle portion of the ␣1 subunit (data not shown) were used. To detect ␤1 sGC, polyclonal anti-␤1 antibodies (26) targeting the COOH terminus were used. Equal sample loading was tested by anti-␣-actin antibodies (Abcam). Antibodies conjugated to horseradish peroxidase (Sigma) were used to visualize the signal by enhanced chemiluminescence (ECL Plus, Amersham). For immunoprecipitation, 250 g of protein from cleared aortic homogenate were incubated with 25 g of polyclonal anti-␤1sGC antibodies (43) overnight at 4°C in 400 l PBS with protease inhibitors. The samples were then combined with 50 l of preequilibrated protein G magnetic beads (Fisher Scientific) and further incubated for 1.5 h at room temperature. The supernatant was removed and saved for Western blots, whereas the beads were washed three times with 40 mM TEA, 200 mM NaCl, 1% Nonidet P-40, pH 7.4. Bound proteins were eluted by boiling in 100 l of Laemmli buffer.
Subcloning and recombinant expression of ␣1-IsoD (␣1-Tr7) in Cos7 cells. A premature stop codon was introduced by QuickChange site-directed mutagenesis (Stratagene) in the ␣1 sGC ORF cloned in pcDNA3.1 (Invitrogen) (26) to generate ␣1-IsoD with a COOHterminal 66 amino acid deletion. Cos-7 cells were grown in DMEM media supplemented with 10% FBS, 0.1 mM MEM non-essential amino acids, and penicillin-streptomycin mixture (50 U/ml and 50 g/ml) at 37°C and 5% CO2. A 10-cm tissue culture dish of 80% confluent Cos-7 cells was transfected with 30 g of pcDNA3.1-␣1 or pcDNA3.1-␣1isoD and 15 g of pcDNA3.1-␤1 plasmids using Lipofectamine LTX/PLUS reagents (Invitrogen), according to manufacturer's instructions. Used plasmid ratio provides equal expression of both subunits. After 48 h, the cells were collected and sonicated in 500 l of 50 mM triethanolamine, pH 7.4, 1 mM DTT, 1 mM EGTA, 1 mM EDTA, protease inhibitors, and 0.1 mM IBMX. Supernatants from 15,000-g centrifugation (15 min at 4°C) were tested for sGC activity.
Assay of sGC activity. Enzymatic activity was assayed using the [ 32 P]GTP-[
32 P]cGMP conversion assay as described previously (31). For activity in lysates from transfected Cos7 cells, 100 g of protein lysate was used in a 10-min assay. For activity in aortic tissue homogenates, 250 g of protein were used in a 25-min assay in the presence of 10 M DEA-NO or 1 M BAY58-2667.
Data analysis. Two-way ANOVA was used to analyze the difference between the control group and groups with descending and ascending aortic aneurysm. Since no statistical difference was detected between the data from aneurysm groups, they were combined and compared with data from the control group. Statistical comparisons between groups were performed by unpaired, two-tailed t-test. P Ͻ 0.05 was considered statistically significant. Data are expressed as means Ϯ SD.
RESULTS

Expression of ␣1 and ␤1 sGC splice forms in human aorta.
Proper expression of sGC genes is vital for maintaining vascular function. Alternative splicing of ␣1 and ␤1 sGC can potentially affect the composition, abundance, and functional properties of sGC protein isoforms expressed in blood vessels. Previous studies demonstrated the expression of human sGC splice forms in cell culture models (42) . To investigate whether ␣1 and ␤1 sGC splice forms are expressed in human vascular tissue, we obtained aortic specimens from donors deceased from causes unrelated to aortic dysfunction (Capital Biosciences). Samples were collected from middle-age or older (70.2 Ϯ 11.7 yr old) donors of both genders (Table 1) . Using RT-PCR analysis with primers targeted to individual ␣1 or ␤1 sGC transcripts, we identified eight different splice forms expressed in full thickness (media and intima layers) of human aorta ( Table 2 ). The current nomenclature of ␣1 and ␤1 sGC splice transcripts and domain organization of corresponding splice protein variants are summarized in Fig. 1 . These data demonstrate that ␣1 and ␤1 sGC genes undergo alternative splicing in human aortic tissue.
Impairment of NO/cGMP signaling is one of the prominent features of vascular dysfunction, systemic arterial hypertension, and atherosclerosis (32, 37) . The expression and activity of sGC is diminished in these conditions (11, 25, 31, 48) . To determine whether sGC splicing and expression is altered in human tissue at late stages of vascular disease, we collected aortic samples from patients who underwent aortic repair surgery due to aortic aneurysm. As presented in Table 1 , samples from 20 middle-age patients (61.3 Ϯ 13.2 yr old) of both sexes were collected for these studies.
The expression of ␣1 and ␤1 sGC transcripts and proteins is altered in aortas with aneurysm. First, we assessed whether total ␣1 or ␤1 sGC mRNA levels differ in samples from control aortas and aortas with aneurysm. Aortic tissue containing both intima and media layers were used for analysis. We performed a qPCR assays using commercial primers (Applied Biosystems) that target amplicons of ␣1 or ␤1 mRNA shared by all of the gene transcripts. Analysis with this pan-specific primers employing comparative ⌬C t method demonstrated 3.2 and 2.3 times increase of, respectively, ␣1 and ␤1 mRNA in samples with aneurysm (Fig. 2) .
However, Western blot analysis of aortic lysates suggested a more complex pattern of expression, as shown in Fig. 3, A and  B . Although the level of canonical full-length ␣1 (isoform ␣1-isoA) sGC protein varied significantly among individuals (Fig. 3A) , overall difference between control and diseased groups (Fig. 3B) was not statistically significant. Opposite to β1-iso 6 (β1Δ 68) [42] βCAT CC β -PAS HNOX
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α1-isoB (C-α1) [10, 23, 43] β1-iso 1 (β1Ω22) [42] α1-isoD α1-isoC (N1-α1) [43] β1-iso 2 (canonical) β1-iso 3 (β1Δ 26Ω6) [42] mRNA data, the level of ␤1 sGC protein was generally higher in control groups than in those with aneurysm (Fig. 3, A and B) . In addition to canonical subunit proteins, we detected a ϳ55-kDa ␣1-immunoreactive band (Fig. 3A) . This band was present primarily in control samples. Out of 11 control samples, 8 samples expressed this band. In five samples, this 55-kDa band was the major ␣1 immunoreactive signal. On the contrary, only 8 of 20 samples with aneurysm expressed this band and at a significantly lower level than in control group.
sGC activity is diminished in aortic samples with aneurysm. Next, we evaluated whether the observed changes in sGC proteins expression are reflected in sGC activity. We measured the cGMP-forming activity in aortic lysates obtained from control and aneurysm groups. As demonstrated in Fig. 3C , NO-induced cGMP-forming activity was higher by 36 Ϯ 3.8% in control samples than in aneurysm samples, indicating that sGC function is diminished in diseased aortic tissue. sGC activity induced by NO-independent heme-replacing sGC activator BAY58-2667 was also lower, albeit only by 14 Ϯ 6%, in samples with aneurysm. BAY58-2667 is a heme-independent sGC activator that has a strong preference toward oxidized or heme-deficient sGC (38) . Together, these data demonstrate that sGC enzymatic activity is decreased in aortas with aneurysm. This decrease in NO-induced activity is most likely associated with a higher content of sGC with dysfunctional heme.
The 55-kDa immunoreactive band is a constituent part of active sGC in human aorta. The 55-kDa band is recognized by highly specific anti-␣1 monoclonal antibodies and displays the same mobility as the recombinant ␣1-isoB sGC (Fig. 3A) . To evaluate the activity of the ␣1-isoB/␤1 heterodimer, we compared the cGMP-forming activity of control samples from patients 6 and 9, who predominantly express, respectively, either ␣1/␤1 or ␣1-isoB/␤1 heterodimer (Fig. 4A, left) . We found that, when normalized to the amount of ␤1 sGC protein, NO-induced sGC activity in lysates was comparable, regardless of whether ␣1-isoA or ␣1-isoB was predominant (Fig. 4A, right) . Next, we investigated whether ␣1-isoB sGC associates with ␤1 sGC subunit. Using anti-␤1 antibodies, we immunoprecipitated the ␤1 subunit from a sample that expresses both ␣1 and ␣1-isoB sGC. The immunoprecipitation was optimized to quantitatively capture the ␤1 subunit in the immunopellet (fraction IP in Fig. 4B ). No ␤1 signal was detected in the unbound fraction (fraction U in Fig. 4B ). Under these conditions, both ␣1-isoA and ␣1-isoB were completely captured in the immunopellet (Fig. 4B) . These results strongly indicate that ␣1-isoB forms a stable heterodimer ␤1 sGC in aortic lysates.
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In addition, we considered whether ␣1-immunoreactive 55-kDa band is the product of degradation of canonical ␣1 sGC subunit. We tested whether incubation of aortic lysates at room temperature diminishes the ␣1-isoA amount or increases the ␣1-isoB amount. As shown in Fig. 4C , we did not observe any changes in protein levels of ␣1-isoA or ␣1-isoB sGC neither in control nor in aneurysm samples over a period of 2 h. All samples used in these studies were collected within this time window and were kept at Ͻ4°C before being frozen in liquid nitrogen. Separately, we confirmed that the patterns of ␣1 and ␤1 sGC immunoreactive bands do not change with prolong storage of aortic tissue at Ϫ80°C (data not shown). These data allow us to conclude that the ϳ55-kDa band is not a degradation product but the ␣1-isoB sGC isoform. Together, stability, immunoprecipitation, and activity data argue that the ␣1-isoB/␤1 heterodimer is expressed in human aorta and supports sGC activity.
The expression of nonfunctional splice forms of ␣1 and ␤1 transcripts is elevated in aortas with aneurysm. Since control aortic samples contained various alternative splice variants of ␣1 and ␤1 sGC subunits, we investigated whether the expres- densitometry data showing the ratio of ␣1 and ␣1-isoB isoforms in samples 6 and 9. Right: the expression of ␣1-isoB compensates for sGC activity in samples with low level of canonical ␣1 subunit. The volume of lysates from control samples 6 and 9 containing equal level of ␤1 subunit was used to determine cGMP-forming activity under basal conditions or in the presence of 10 M DEA-NO. Data are means Ϯ SD (n ϭ 4).The P values are indicated. B: the ␣1-isoB variant co-precipitates with ␤1 sGC subunit; lysate from sample 11 ( Fig. 3) was incubated with polyclonal anti-␤1 sGC antibodies and pooled down with protein G magnetic beads, as detailed in MATERIAL AND METHODS. The lysate (L), immunopellet (IP), and unbound samples (U) were probed by Western blotting using monoclonal anti-␣1 or polyclonal anti-␤1 antibodies. C: the immunoreactive ϳ55-kDa ␣1-isoB band is not a degradation product of canonical ␣1 sGC protein; the intensity of ␣1 and ␣1-isoB bands in aortic lysates does not change even after 2 h of incubation at room temperature.
sion of individual splice form transcripts is altered in aortas with aneurysm. Using a semi-quantitative RT-PCR analysis with splice form-specific primers, we observed that the patterns of expression of individual sGC splice transcripts do not always coincide with the overall increased of total sGC mRNA in aneurysm group (Figs. 5 and 6). Consistent with pan-specific qRT-PCR, the level of transcripts ␣1-Tr1 (protein isoform ␣1-isoA), ␣1-Tr6 (protein isoform ␣1-isoC), and ␣1-Tr7 (protein isoform ␣1-isoD) were higher in diseased aortas (Fig. 5) . The ␣1-isoC isoform lacks the COOH-terminal catalytic domain (Fig. 1) and is catalytically inactive. In fact, previous in vitro studies demonstrated that the ␣1-isoC variant is inhibitory when co-expressed with canonical ␣1-isoA/␤1 sGC (43) . The level of ␣1-Tr7, encoding isoform ␣1-isoD, was several times higher in aneurysm samples. Isoform ␣1-isoD lacks 66 COOH-terminal residues ( Fig.  1 ) and has impaired enzymatic activity (see below). On the contrary, the level of ␣1-Tr5, encoding oxidation-resistant ␣1-isoB, was lower in aneurysm samples. Thus, despite the overall increase in ␣1 sGC mRNA in aneurysm samples, the transcripts coding for dysfunctional ␣1-isoC and ␣1-isoD variant were also increased, whereas the transcript coding for functional ␣1-isoB was diminished.
For ␤1 sGC splice variants, the difference between control and aneurysm groups was less pronounced. The lack of a unique sequence specific for canonical transcript 2 ␤1 sGC prevented us from evaluating the level of ␤1-Tr2 alone without the input of other splice variants. However, we were able to assess the level of other ␤1 splice transcripts. We found that the expression of ␤1-Tr1, ␤1-Tr4, and ␤1-Tr6 transcripts was higher in aneurysm group (Fig. 6) . The ␤1-Tr1 transcript encodes the ␤1-isoform 1 protein, an isoform that contains a 22-amino acid insertion in the HNOX domain (see Fig. 1 ). The HNOX domain of sGC is responsible for heme and NO binding. Therefore, the insertion in that area should negatively affect the binding of heme in ␤1-iso1 protein. The ␤1-Tr6 transcript encodes the ␤1-isoform 6 protein with a large 68-amino acid deletion in HNOX domain (see Fig. 1 ). This ␤1-isoform 6 sGC also should have an impaired heme function. The ␤1-isoform 4 sGC, encoded by the ␤1-Tr4 transcript, not only carries the same 68-residue deletion but also a 43-amino acid insertion close to the catalytic domain (see Fig. 1 ). Although ␤1 sGC splice forms are not yet biochemically characterized, alterations in proteins they encode suggest that respective sGC heterodimers would have impaired NO stimulation and diminished cGMP-forming activity. ␣1-IsoD/␤1 heterodimer has a diminished activation response. RT-PCR analysis indicated that ␣1-Tr7 splice transcript is barely detectable in control aortas but is well represented in aneurysm samples (Fig. 5) . The ␣1-Tr7 transcript encodes the ␣1-isoD protein isoform, which lacks 66 residues at the COOH terminus. To understand how the presence of ␣1-isoD might affect the overall sGC function in aorta, we evaluated enzymatic properties of recombinant ␣1-IsoD subunit. The plasmid that expresses ␣1-IsoD variant was generated and transfected into Cos7 cells together with the plasmid expressing canonical ␤1 sGC subunit. Cos7 cells lack endogenous sGC expression and are widely used to evaluate the properties of recombinant sGC (27) . The lysates from Cos7 cells expressing ␣1-IsoD and ␤1 sGC displayed a detectable basal cGMP-forming activity, confirming the formation of a catalytically competent ␣1-isoD/␤1 heterodimer (Fig. 7) . However, the activity of ␣1-IsoD/␤1 sGC was only marginally induced by 1 M NO treatment or by a combination of NO and allosteric sGC stimulator BAY41-2272, in contrast to strong activation of canonical ␣1/␤1 sGC. Another allosteric sGC stimulator dicyanocobinamide CN2-Cbi, which activate sGC independently of heme status (41), induced only a marginal increase of the basal activity in ␣1-IsoD/␤1-containing lysates. These data demonstrate that ␣1-IsoD/␤1 heterodimer has a significantly impaired activation capacity, suggesting that increased expresson of ␣1-IsoD should interfere with sGC function in vascular cells. Therefore, it is important to understand the processes affecting expression of functional sGC in normal and diseased human vasculature. It has been reported that expression of sGC protein is regulated by a combination of transcriptional, posttranscriptional, translational, and protein stability processes (35, 42) . The heterodimeric sGC structure adds a higher level of complexity, since changes in expression of even one subunit affect sGC activity. In this report, we demonstrate that ␣1 and ␤1 sGC genes undergo extensive alternative splicing in human aortic tissue. We found that in human aorta each gene is represented by four different spliced forms, which encode unique protein variants ( Fig. 1; Table 2 ). Moreover, we report that the abundance and composition of sGC splice forms differs between aortas with and without aneurysm. Interestingly, the diversity of mammalian sGC splice forms seems to be restricted to humans. Presently, there are very few alternative splice variants of sGC detected in rodents, most of which do not have direct human orthologs (NCBI database, http:// www.ncbi.nlm.nih.gov/).
An unexpected finding was that qPCR analysis with panspecific primers demonstrated a two-to threefold increase of total amount of ␣1 and ␤1 sGC transcripts in diseased samples. However, this increase in total sGC transcripts did not result in higher level of functional sGC protein. On the contrary, aortas with aneurysm had the same expression of canonical full-size ␣1-IsoA sGC and a lower level of ␤1 sGC than control aortas. We also found that most control aortas highly express the ␣1-IsoB splice form, which was the major ␣1 protein in some samples. The expression of 55-kDa ␣1-isoB immunoreactive band was reported previously in human brain (18) . Without the benefit of current bioinformatics data, the band was considered the product of a degradation process that occurs in vivo but not in vitro. Immunoprecipitation studies and activity evaluation presented in this report clearly demonstrate that ␣1-IsoB forms a functional heterodimer with ␤1 subunit in aorta in vivo, validating previous in vitro observations (23, 43) . However, aortas with aneurysm had only traces of the ␣1-IsoB protein and a much lower level of the respective ␣1-Tr 5 transcript. We have previously reported that ectopic expression of ␣1-IsoB protects ␤1 sGC subunit from oxidative protein degradation (43) . Slightly higher levels of ␤1 protein observed in control samples are perhaps the result of this protective function.
Expression of ␣1-Tr6 and ␣1-Tr7 transcripts, coding for ␣1-isoC and ␣1-IsoD protein isoforms, was elevated in aortas with aneurysm. Previous studies demonstrated that ␣1-IsoC inhibits sGC activity (43) , whereas data presented in this report demonstrate that ␣1-IsoD does not support sGC activation (Fig. 7) . The levels of ␤1-Tr1, ␤1-Tr4, and ␤1-Tr6 splice transcripts, encoding protein isoforms ␤1-Iso1, ␤1-Iso4, and ␤1-Iso6 sGC, were also elevated in aortas with aneurysm. Current understanding of sGC structure and function (13) predicts with a high degree of confidence that insertions and deletions in the heme-binding domain of these ␤1 sGC splice isoforms will result in heterodimers with significantly impaired heme content and activation by NO. Therefore, analysis of expression of individual ␣1 and ␤1 sGC splice forms indicates that the composition of sGC transcripts in aortas with aneurysm is altered in favor of nonfunctional or partially functional sGC splice variants. These changes predict a diminished sGC function in vasculature. This conclusion is directly confirmed by sGC activity measurements. NO-dependent sGC activity was lower by 36% in aortas with aneurysm, suggesting impaired sGC function in these samples. Even more revealing is that the difference between sGC activity in control aortas and aortas with aneurysm was less pronounced when it was probed by BAY58-2667, an activator that preferentially targets hemedeficient sGC, or sGC with oxidized heme (45) . These data indicate that aortas with aneurysm have a higher content sGC with deficient/oxidized heme. sGC is expressed in smooth muscle and endothelial cells of both vascular cell types. Considering that the monolayer of endothelial cells has a relatively small contribution to the total amount of protein or RNA material isolated from investigated aortic samples, our findings most likely reflect the changes in sGC splicing occurring in the more abundant vascular smooth muscle cells.
It is important to note that multiple risk factors contribute to the development of aortic aneurysm. Only 20% of cases are considered to have genetic predisposition (28) . Other risk factors include alterations in the direct mechanical forces on the aortic wall (i.e., hypertension, hypervolemia, derangements of aortic flow) and abnormalities in intrinsic properties of aortic tissue (connective tissue disorders or direct chemical damage) (17) . Uncontrolled hypertension is present in 70% of individuals with thoracic aortic diseases (6) . Both atherosclerosis and hypertension have been associated with diminished sGC expression and function (11, 25, 31, 48) . As represented in Table 1 , diseased samples were collected from patients with descending or ascending aortic aneurysm, which have different etiologies. Nevertheless, when the groups with descending or ascending aortic aneurysm were analyzed separately, the changes in the composition and abundance of sGC splice transcripts between these two groups were not statistically significant (results not shown). Many donors in disease group had preexisting cardiovascular conditions before the development of aneurysm; most samples had clear signs of atherosclerosis (not shown), and a significant number of donors had been diagnosed with hypertension (Table 1) . Individuals from the control group, although not diagnosed with aortic dysfunctions, deceased from a variety of causes. It is revealing that, despite the great variability between donors' preexisting cardiovascular abnormalities, age, and sex differences, differences in sGC splicing were well pronounced between healthy and diseased aortas. These data argue that sGC splicing is an important, previously unrecognized factor contributing to the development of vascular disease.
It has been demonstrated that inflammatory conditions, including exposure to several cytokines and increased concentrations of reactive oxygen species (ROS), decrease the expression of sGC (42) . In cell culture models, when oxidative stress was mimicked by treatments with H 2 O 2 (10) or pharmacological oxidation of sGC heme (43) , the apparent half-life of canonical sGC was ϳ5 h. Co-expression of ␣1-isoB splice form, which has a much longer half-life, resulted in significant stabilization of sGC. Oxidative stress is known to persist in vascular disorders and to increase with age, which may explain accumulation of ␣1-IsoB in control aortas. Therefore, increased ␣1-isoB expression observed in control aortas in the present report may be a positive factor contributing to the maintenance of sGC function under oxidative stress conditions. On the contrary, diminished expression of ␣1-isoB compounded by increased expression of dysfunctional sGC splice forms should diminish sGC function, further exacerbating the dysfunction of NO/cGMP signaling in diseased vasculature. This should negatively affect not only vascular relaxation but also cellular differentiation and vascular remodeling (24, 30, 40) . Further studies are needed to understand the contribution of individual sGC splice forms to the development of aortic aneurysm.
The patients recovering after aortic repair surgeries are under a complex drug regimen, which in most cases includes sGC-targeting nitrovasodilators. Within the last decade, a number of NO-independent sGC regulators have been developed and are undergoing clinical trials or have been approved for treatment (44, 46) . The efficacy of sGC-targeting drugs is strongly affected by the level and functional state of sGC enzyme. Therefore, determining the composition and ratio of sGC isoforms in surgically removed aortic samples may provide necessary information for optimizing personalized sGCtargeting therapy in postsurgical patients. Although more extensive validation is needed, the levels for transcripts ␣1-Tr6 and ␣1-Tr7 and ␤1-Tr4 may be important indicators of impaired NO/cGMP signaling.
Emerging new strategies allow for targeted manipulations of RNA splicing (50) . Stable interfering morpholino RNA oligonucleotides are currently being developed to alter and/or control splicing of selected genes, e.g, splicing correction using this method is presently under development for the treatment of ␤-thalassemia (26) and cystic fibrosis (16) , among other things. This technology potentially provides new therapeutic tools modulating sGC function in cardiovascular diseases to restore the composition of sGC splice transcripts featured in healthy blood vessels.
In summary, our report provides the first clear evidence for alternative splicing of ␣1 and ␤1 sGC in human vasculature. The data presented here indicate that alternative splicing may contribute to impairment of sGC function in aortic aneurysm. Precise understanding of sGC splicing regulation should help to develop new approaches to treatment of vascular dysfunction and assist in optimizing personalized sGC-targeting treatments.
